MEET OUR TEAM

Please meet the people behind our company, led by Tom Wiggans, with additional industry veterans from Connetics, Peplin, Stiefel and Gilead.

TECHNOLOGY SPOTLIGHT

Cimzia®, our lead product candidate, is a PEGylated, humanized antigen-binding mAb fragment TNF inhibitor in development for the treatment of moderate-to-severe plaque psoriasis.

Dermira and UCB announce start of Phase 3 program for CIMZIA® (certolizumab pegol) in psoriasis

Menlo Park, Calif., and Brussels, Belgium, January 8, 2015 – Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biopharmaceutical leader (Euronext: UCB), announced today that the first patients have been dosed in the Phase 3 clinical program… View Article

Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients.